Postmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval

This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.

Corresponding Author: Maryam Mooghali, MD, MSc, Department of Internal Medicine, Yale New Haven Hospital, 20 York St, New Haven, CT 06510 (maryam.mooghali@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.